NCT03508401

Brief Summary

Acute circulatory failure is frequent, affecting up to one-third of patients admitted to intensive care units (ICU). Monitoring hemodynamics and cardiac function is therefore a major concern. Analysis of respiratory diameter variations of the superior vena cava (SVC) is easily obtained with transesophageal echocardiography (TEE) and is helpful to assess fluid responsiveness. Transthoracic echocardiography (TTE) exploration of the SVC is not used in routine. Recently, micro-convex ultrasound transducers have been marketed and these may be of use for non-invasive SVC flow examination. However, analysis of diameter variations of the SVC with TTE does not seem to be possible since the approach from the supraclavicular fossa does not allow for a good visualization of the SVC walls. It was recently demonstrated in a short pilot study that TTE examination of the SVC flow with a micro-convex ultrasound transducer (GE 8C-RS) seems both easy to learn and to use (feasibility = 84.9%), and is reproducible in most ventilated ICU patients with an intraclass correlation coefficient for the systolic fraction of the superior vena cava flow of 0.90 (95% confidence interval \[0.86-0.93\]). The hypothesis is that cardio-respiratory interactions in intubated-ventilated patients are responsible of SVC flow variations and that the analysis of the SVC flow respiratory variations could be a new predictive tool of fluid responsiveness.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
188

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2018

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 16, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

April 25, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

May 25, 2018

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 25, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 25, 2020

Completed
Last Updated

May 31, 2018

Status Verified

May 1, 2018

Enrollment Period

2 years

First QC Date

April 16, 2018

Last Update Submit

May 30, 2018

Conditions

Keywords

superior vena cava

Outcome Measures

Primary Outcomes (1)

  • ventricular outflow tract velocity time index (LVOT TVI)

    Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf). ΔSVCf is calculated as(VTImax- VTImin )/(1/2(VTImax+ VTImin))

    The day of inclusion

Secondary Outcomes (2)

  • optimal cut-off value of ΔSVCf to predict fluid-responsiveness

    The day of inclusion

  • proportion of patients in which measurement of ΔSVCf is not possible

    The day of inclusion

Study Arms (1)

ICU intubated patients

EXPERIMENTAL

After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR Patients will be classified in two groups according to the hemodynamic response to PLR : * Patients are responders if LVOT VTI increases of at least 10% after PLR * patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR.

Other: Passive leg raising (PLR)Device: Echo-Doppler measurements

Interventions

PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload. PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs

ICU intubated patients

Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf). ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin)).

ICU intubated patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult patients (≥ 18 years old)
  • Admission in ICU after tracheal intubation or tracheal intubation during the ICU stay
  • Volume-controlled ventilation with a tidal volume of 8 mL/kg

You may not qualify if:

  • Persistence of spontaneous breathing
  • Cardiac arrhythmia
  • Severe Acute Respiratory Distress Syndrome, defined as PaO2/FIO2 ratio \< 100
  • Acute right ventricular failure defined by S'VD \< 10 cm or Tricuspid Annular Plane Systolic Excursion (TAPSE) \< 10 mm measured with Transthoracic Echocardiography (TTE)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Département d'Anesthésie-Réanimation, Hôpital Edouard Herriot,

Lyon, 69003, France

RECRUITING

Central Study Contacts

Bertrand DEVIGNE, M.D, PhD

CONTACT

Guillaume MARCOTTE, M.D, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 16, 2018

First Posted

April 25, 2018

Study Start

May 25, 2018

Primary Completion

May 25, 2020

Study Completion

May 25, 2020

Last Updated

May 31, 2018

Record last verified: 2018-05

Locations